Genmab A/S is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company specializes in the development of differentiated antibody therapeutics for the treatment of cancer. Genmab A/S is listed on the NASDAQ OMX Copenhagen and NASDAQ OMX New York and went public in 2000.
The company's lead product is Darzalex (daratumumab), a monoclonal antibody that is used for the treatment of multiple myeloma. Darzalex was approved by the U.S. Food and Drug Administration (FDA) in 2015 and has since become a blockbuster drug, generating billions of dollars in annual sales. Genmab A/S has collaborations with several pharmaceutical companies, including Johnson & Johnson and Novartis, to develop additional cancer treatments.
Genmab A/S has a proprietary technology platform for the discovery and development of antibodies, known as the DuoBody platform. This platform allows the company to create bispecific antibodies, which are capable of binding to two different targets at once. The DuoBody platform has the potential to create more effective cancer treatments with fewer side effects compared to traditional chemotherapy.
In addition to its cancer treatments, Genmab A/S has a pipeline of products in development for the treatment of other diseases, including autoimmune disorders and infectious diseases. The company is also exploring the potential of its technology platform to develop bispecific antibodies for use in immunotherapy, which is an emerging area of cancer treatment.
As of 2021, Genmab A/S has a market capitalization of approximately $30 billion and employs more than 800 people in locations around the world, including the United States and Japan. The company has received numerous awards for its innovative research and development, including the Lasker-DeBakey Clinical Medical Research Award in 2016 for the development of Darzalex.